Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated & Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq, Octanate or Wilate - Efficacy & Safety Observational Study-Protect-NOW

Next Previous
Trial Profile

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated & Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq, Octanate or Wilate - Efficacy & Safety Observational Study-Protect-NOW

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary) ; Simoctocog alfa
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Protect-NOW
  • Sponsors Octapharma

Most Recent Events

  • 06 Jun 2024 Planned End Date changed from 1 Jun 2030 to 30 Jun 2030.
  • 07 Nov 2023 Planned number of patients changed from 140 to 200.
  • 15 Jul 2022 Trial design, published in the Internet Document

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top